Intended for healthcare professionals


NEJM editor gives pretrial evidence in Vioxx case

BMJ 2006; 332 doi: (Published 02 February 2006) Cite this as: BMJ 2006;332:255
  1. Janice Hopkins Tanne
  1. New York

    Trials of three civil actions starting in the United States this month will examine whether Merck's cyclo-oxygenase-2 painkiller Vioxx (rofecoxib) caused the plaintiffs' heart attacks. Lawyers for both plaintiffs and Merck have claimed that editorial information ordered by the court from the New England Journal of Medicine will help their cases on whether Merck promptly and accurately disclosed the drug's cardiac risks.

    Gregory Curfman, the executive editor of the New England Journal of Medicine, last week gave a deposition—a sworn pretrial “discovery” testimony—in connection with the forthcoming retrial of a federal case originally tried in …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription